|
|
Article: Neurocrine Biosciences Reports Positive Results From First Phase III Clinical Trial With indiplon-IR in 593 Subjects With Transient Insomnia.
- Article from:
- PR Newswire
- Article date:
- November 14, 2002
|
Copyright informationCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Indiplon-IR Demonstrates Statistically Significant Improvement in Multiple Sleep Endpoints
Neurocrine Biosciences, Inc. today announced positive results from the Company's first Phase III clinical trial with indiplon-IR capsules, achieving both primary and secondary endpoints of sleep initiation. The study enrolled 593 subjects with Transient Insomnia. Results demonstrated that indiplon-IR was safe, well tolerated, and effective in these subjects with Transient Insomnia, achieving rapid sleep induction without next day residual effects. The study was a randomized, double-blind, placebo-controlled, parallel group Phase III clinical trial designed to assess the ...